{"id":69370,"date":"2024-02-07T13:54:13","date_gmt":"2024-02-07T05:54:13","guid":{"rendered":"https:\/\/naipnews.naipo.com\/?p=69370"},"modified":"2026-08-05T14:21:28","modified_gmt":"2026-08-05T06:21:28","slug":"2024%e5%b9%b413%e7%a7%8d%e6%9c%80%e5%80%bc%e5%be%97%e5%85%b3%e6%b3%a8%e7%9a%84%e8%8d%af%e7%89%a9-%e4%b8%8a","status":"publish","type":"post","link":"https:\/\/naipnews.naipo.com\/zh-hans\/69370\/","title":{"rendered":"2024\u5e7413\u79cd\u6700\u503c\u5f97\u5173\u6ce8\u7684\u836f\u7269 (\u4e0a)"},"content":{"rendered":"
\"\"
\u56fe\u7247\u6765\u6e90 : shutterstock\u3001\u8fbe\u5fd7\u5f71\u50cf<\/figcaption><\/figure>\n

\u5177\u5f71\u54cd\u529b\u7684\u8c03\u7814\u673a\u6784\u79d1\u777f\u552f\u5b89(CLARIVATE PLC<\/a>) \u4e8e2024 \u5e741\u67088\u65e5\u53d1\u8868\u4e86\u300a2024\u6700\u503c\u5f97\u5173\u6ce8\u7684\u836f\u7269\u300b[1]<\/a>\u00a0(Drugs to Watch 2024 – New frontiers in medicine)\u8c03\u7814\u62a5\u544a (\u4e0b\u79f0\u300a\u62a5\u544a\u300b)\uff0c\u62a5\u544a\u5c06\u91cd\u70b9\u653e\u5728\u65b0\u836f\u7684\u53d1\u73b0\u3001\u7814\u53d1\u548c\u65bd\u7528\u6240\u5e26\u6765\u7684\u4e00\u4e9b\u5f71\u54cd\uff0c\u5e76\u805a\u7126\u4e8e\u5728\u672a\u6765\u51e0\u5e74\u5185\u53ef\u80fd\u5e26\u6765\u91cd\u8981\u8f6c\u6298\u70b9\u7684\u836f\u7269\u4e0e\u5176\u5019\u9009\u836f\u7269\uff0c\u56e0\u4e3a\u5b83\u4eec\u5c06\u6709\u673a\u4f1a\u6210\u4e3a\u7545\u9500\u7684\u6216\u5177\u91cd\u5927\u8fdb\u5c55\u6027\u7684\u836f\u7269\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u79d1\u777f\u552f\u5b89\u7684\u7cfb\u5217\u62a5\u544a\u5bf9\u6301\u7eed\u53d1\u5c55\u7684\u533b\u7597\u4fdd\u5065\u9886\u57df\u6765\u8bf4\uff0c\u662f\u76f8\u5f53\u91cd\u8981\u7684\u4ea7\u4e1a\u8d44\u6e90\uff0c\u5728\u8fc7\u53bb11\u5e74\u53d1\u5e03\u7684\u62a5\u544a\u4e2d\uff0c\u5df2\u786e\u8ba4\u4e86\u8d85\u8fc7 85 \u79cd\u6700\u503c\u5f97\u5173\u6ce8\u7684\u836f\u7269\u3002<\/p>\n

\u300a\u62a5\u544a\u300b\u5217\u51fa2024\u5e74\u6700\u503c\u5f97\u5173\u6ce8\u7684\u836f\u7269\u670913\u79cd\u836f\u7269\uff0c\u672c\u6587\u5c06\u5206\u4e3a\u4e0a\u3001\u4e0b2\u7bc7\u8be6\u7ec6\u4ecb\u7ecd\u8be513\u79cd\u836f\u7269\u7684\u4f5c\u7528\u65b9\u5f0f\u3001\u4e34\u5e8a\u9002\u5e94\u75c7\u3001\u53ca\u8be5\u836f\u7269\u503c\u5f97\u5173\u6ce8\u7684\u7406\u7531\u4e0e\u5176\u9884\u671f\u9500\u552e\u989d\u3002\u4e0a\u7bc7\u4f1a\u7387\u5148\u4ecb\u7ecd\u5176\u4e2d5\u79cd\u836f\u7269\u3002<\/p><\/blockquote>\n

2023\u300a\u6700\u503c\u5f97\u5173\u6ce8\u7684\u836f\u7269\u300b\u56de\u987e<\/span><\/p>\n

\u57282023\u5e74\u7684\u300a\u6700\u503c\u5f97\u5173\u6ce8\u7684\u836f\u7269\u300b \u540d\u5355\u4e2d\uff0c\u79d1\u777f\u552f\u5b89\u6807\u6ce8\u4e8614\u79cd\u5927 \/ \u5c0f\u5206\u5b50\u836f\u7269\u4f5c\u4e3a\u6700\u503c\u5f97\u5173\u6ce8\u7684\u836f\u7269\u3002\u5176\u4e2d\uff0c\u670912\u79cd\u5df2\u7ecf\u83b7\u5f97FDA\u7684\u6838\u51c6\uff0c\u5e76\u4e14\u5df2\u7ecf\u4e0a\u5e02\u6216\u6b63\u5728\u51c6\u5907\u4e0a\u5e02\u3002\u6bcb\u5eb8\u7f6e\u7591\uff0c\u8fc4\u4eca\u4e3a\u6b62\u6700\u4e3a\u6210\u529f\u7684\u836f\u7269\u83ab\u8fc7\u4e8e2023\u5e74\u6240\u5217\u540d\u5355\u4e2d\u4e4b\u5fc5\u6cbb\u59a5\u65bd\u8d35\u5b9d (Bristol Myers Squibb) \u836f\u5382\u7684Sotyktu\u2122 (deucravacitinib)\uff0c\u5176\u4e3a\u4e00\u79cd\u916a\u80fa\u9178\u6fc0\u91762\u6291\u5236\u5242 (tyrosine kinase 2 inhibitor)\uff0c\u53ef\u4f7f\u7528\u4e8e\u6cbb\u7597\u4e2d\u5ea6\u81f3\u91cd\u5ea6\u7684\u6591\u5757\u6027\u5e72\u7663 (plaque psoriasis)\u3002\u5176\u836f\u5382\u62a5\u544a\u6307\u51fa\u8be5\u836f\u7269\u5177\u5f3a\u800c\u6709\u529b\u7684\u8d77\u59cb\u4f18\u52bf\uff0c\u56e0\u4e3a\u8be5\u836f\u7269\u4e8e2023\u5e74\u524d9\u4e2a\u6708\u7684\u9500\u552e\u989d\u8fbe1.07\u4ebf\u7f8e\u5143\u3002\u5fc5\u6cbb\u59a5\u65bd\u8d35\u5b9d\u836f\u5382\u76f8\u4fe1\uff0c\u5df2\u6709\u7ea610%\u7684\u60a3\u8005\u4f7f\u7528\u8be5\u836f\u7269\uff0c\u5e76\u9884\u671f\u57282024\u5e74\u5c06\u8fdb\u4e00\u6b65\u6269\u5927\u8be5\u836f\u7269\u7684\u4f7f\u7528\u7387\u3002<\/p>\n

\u4f46\u90e8\u5206\u521b\u65b0\u836f\u7269\u4e4b\u7814\u53d1\u4ecd\u5904\u4e8e\u56f0\u5883\u4e2d\uff0c\u6cbb\u7597\u963f\u5179\u6d77\u9ed8\u75c7(Alzheimer\u2019s disease)\u7684\u836f\u7269\u5373\u4e3a\u5176\u4e2d\u4e4b\u4e00\u30022023\u5e74\u7684\u540d\u5355\u5173\u6ce8\u4e86\u4e24\u79cd\u4e0d\u540c\u7c7b\u6cbb\u7597\u673a\u5236\u7684\u836f\u7269\uff0c\u5176\u4e00\u4e3a\u4ee5\u03b2\u6dc0\u7c89\u6837\u86cb\u767d\u4e3a\u6807\u9776 (beta amyloid-targeting) \u7684\u536b\u91c7 (Eisai) \u836f\u5382\u7684LEQEMBI\u00ae(Lecanemab)\uff0c\u8be5\u836f\u7269\u4e8e2023\u5e746\u6708\u83b7\u5f97\u4e86FDA\u5168\u9762\u6838\u51c6\u3002\u536b\u91c7\u836f\u5382\u7684\u62a5\u544a\u6307\u51fa\uff0c\u60a3\u8005\u4f7f\u7528\u8be5\u836f\u7269\u7684\u60c5\u51b5\u7b26\u5408\u9884\u671f\u7ed3\u679c\uff0c\u5e76\u4e14\u9884\u4f30\u4e8e2024\u5e74\u60a3\u8005\u7684\u4f7f\u7528\u91cf\u4f1a\u518d\u4e0a\u5347\u3002\u800c\u53e6\u4e00\u60c5\u51b5\u4e0d\u592a\u7406\u60f3\u8005\u7684\u662f\u793c\u6765(Lilly)\u836f\u5382\u7684Donanemab\u3002\u6b64\u5916\uff0c\u57282023\u5e74\u6240\u5217\u7684\u6b21\u4e16\u4ee3\u836f\u7269 (next – generation medicines) \u4e2d\uff0c\u8f83\u503c\u5f97\u5173\u6ce8\u8005\u5982\u53cc\u7279\u5f02\u6027\u6297\u4f53 (bispecific antibody) \u53ca\u57fa\u56e0\u7597\u6cd5 (gene therapy)\u3002\u5c5e\u4e8e\u53cc\u7279\u5f02\u6027\u6297\u4f53\u8005\uff0c\u805a\u7126\u4e8e\u5a07\u751f (Johnson & Johnson) \u836f\u5382\u4e4b\u6cbb\u7597\u591a\u53d1\u6027\u9aa8\u9ad3\u7624 (multiple myeloma) \u4e4bTECVAYLI\u00ae (Teclistamab)\uff0c\u8be5\u836f\u7269\u7684\u6cbb\u7597\u6210\u679c\u6709\u4e0d\u9519\u7684\u8868\u73b0\uff1b\u4f46\u767e\u50b2\u4e07\u91cc (BioMarin) \u836f\u5382\u4e4b\u6cbb\u7597A\u578b\u8840\u53cb\u75c5 (hemophilia A) \u4e4bROCTAVIAN\u2122 (valoctocogene roxaparvovec) \u57fa\u56e0\u7597\u6cd5\u7684\u8868\u73b0\u5219\u4e0d\u5982\u9884\u671f\u3002<\/p>\n

2024\u5e74\u300a\u6700\u503c\u5f97\u5173\u6ce8\u7684\u836f\u7269\u300b\u6982\u89c2<\/span><\/p>\n

\u57282024\u5e74\u300a\u62a5\u544a\u300b\u4e2d\uff0c\u91cd\u70b9\u5173\u6ce8\u672a\u67655\u5e74\u5185\u53ef\u80fd\u5e26\u6765\u91cd\u8981\u8f6c\u6298\u70b9\u6216\u6539\u53d8\u73b0\u6709\u6cbb\u7597\u6a21\u5f0f\u7684\u836f\u7269\u3002\u79d1\u777f\u552f\u5b89\u7684\u5206\u6790\u5e08\u4e8e\u300a\u62a5\u544a\u300b\u4e2d\u786e\u5b9a\u4e8613\u79cd\u5c06\u4e8e2024\u5e74\u4e0a\u5e02\u7684\u65b0\u7597\u6cd5\u548c\u836f\u7269\uff0c\u5e76\u9884\u6d4b\u5c06\u57282029\u5e74\u8fbe\u5230\u91cd\u78c5\u70b8\u5f39\u5730\u4f4d\uff0c\u6216\u4e3a\u60a3\u8005\u5e26\u6765\u6539\u53d8\u6e38\u620f\u89c4\u5219\u7684\u597d\u5904\u3002\u8fd9\u4e9b\u53d1\u5c55\u524d\u666f\u770b\u597d\u7684\u836f\u7269\u5305\u62ec\u9488\u5bf9\u4e73\u817a\u764c\u3001A\u578b\u8840\u53cb\u75c5\u3001\u9570\u5200\u5f62\u72b6\u8840\u7403\u8d2b\u8840\u75be\u75c5\u3001\u514b\u9686\u6c0f\u75c7\u3001\u6e83\u75a1\u6027\u7ed3\u80a0\u708e\u3001\u4eba\u7c7b\u547c\u5438\u9053\u878d\u5408\u75c5\u6bd2(RSV)\u611f\u67d3\u548c\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u7b49\u75be\u75c5\u7684\u5e7f\u6cdb\u6cbb\u7597\u521b\u65b0\u3002\u6b64\u5916\uff0c\u300a\u62a5\u544a\u300b\u8fd8\u7126\u70b9\u5173\u6ce8\u4e86\u4e2d\u56fd\u5927\u9646\u4e0d\u65ad\u589e\u957f\u7684\u6162\u6027\u75c5\u5e02\u573a\uff0c\u91cd\u70b9\u4ecb\u7ecd\u4e867\u79cd\u836f\u7269\uff0c\u8fd9\u4e9b\u836f\u7269\u53ef\u80fd\u57282029 \u5e74\u8fbe\u523010 \u4ebf\u7f8e\u5143\u7684\u91cd\u78c5\u5730\u4f4d\uff0c\u6216\u5bf9\u9700\u8981\u66f4\u597d\u6cbb\u7597\u9009\u62e9\u7684\u4e2d\u56fd\u5927\u9646\u60a3\u8005\u4ea7\u751f\u91cd\u5927\u5f71\u54cd\u3002<\/p>\n

\u5728\u7814\u7a76\u65b9\u6cd5\u90e8\u5206\uff0c\u79d1\u777f\u552f\u5b89\u7684\u5206\u6790\u5e08\u6240\u5206\u6790\u7684\u8303\u56f4\u6db5\u76d6\u6570\u767e\u79cd\u75be\u75c5\u3001\u836f\u7269\u548c\u5176\u5e02\u573a\u7b49\u4e4b\u6570\u636e\uff0c\u5e76\u4f9d\u636e\u9884\u671f\u6838\u51c6\u6216\u4e0a\u5e02\u65e5\u671f\u3001\u7ade\u4e89\u8d44\u6599\u3001\u836f\u7269\u76d1\u7ba1\u72b6\u51b5\u3001\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c\u3001\u5e02\u573a\u52a8\u6001\u548c\u5176\u4ed6\u56e0\u7d20\u7b49\u5f71\u54cd\u56e0\u5b50\uff0c\u5bf9\u6bcf\u79cd\u836f\u7269\u8fdb\u884c\u8bc4\u4f30\u3002\u7b5b\u9009\u7684\u6807\u51c6\u4e3a\u836f\u7269\u5904\u4e8e\u7b2c\u4e8c\u671f\u6216\u7b2c\u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3001\u5373\u5c06\u7533\u8bf7\u6838\u51c6\u6216\u6b63\u5728\u7533\u8bf7\u6838\u51c6\u4e4b\u9636\u6bb5\u6216\u5df2\u4e8e2023\u5e74\u521d\u4e0a\u5e02\u4e4b\u5019\u9009\u836f\u7269\uff0c\u5e76\u8fdb\u884c\u8fdb\u4e00\u6b65\u4e4b\u5206\u6790\u3002\u6240\u6392\u9664\u8005\u4e3a2023\u5e74\u4e4b\u524d\u5df2\u4e0a\u5e02\u4e4b\u836f\u7269\u3002<\/p>\n

2024\u5e74\u503c\u5f97\u5173\u6ce8\u7684\u836f\u7269 \u2013 \u7b2c\u4e00\u90e8\u5206<\/span><\/p>\n

\u88ab\u79d1\u777f\u552f\u5b89\u5217\u4e3a2024\u5e74\u503c\u5f97\u5173\u6ce8\u7684\u836f\u7269\u670913\u79cd\u836f\u7269\uff0c\u6309\u5176\u5b57\u6bcd\u987a\u5e8f\u6392\u5217\u5982\u4e0b\uff1a<\/p>\n

\u25cf\u00a0Aflibercept (\u9ad8\u5242\u91cf\uff0chigh dose)<\/strong>[2]<\/a><\/span><\/p>\n

Aflibercept\u662f\u4e00\u79cd\u91cd\u7ec4\u7684\u878d\u5408\u86cb\u767d\u8d28\uff0c\u542b\u6709\u7531\u4eba\u7c7b\u5185\u76ae\u7ec6\u80de\u751f\u957f\u56e0\u5b50 (vascular endothelial growth factor\uff0c VEGF) \u63a5\u53d7\u56681\u4e0e\u5185\u76ae\u7ec6\u80de\u751f\u957f\u56e0\u5b50\u63a5\u53d7\u56682\u7684\u80de\u5916\u533a\u57df\u4e0e\u4eba\u7c7b\u514d\u75ab\u7403\u86cb\u767dG1 (immunoglobulin G 1\uff0cIgG 1) Fc\u90e8\u4f4d\u878d\u5408\u800c\u6210\u3002Aflibercept\u4f5c\u4e3a\u4e00\u79cd\u53ef\u6eb6\u6027\u8bf1\u9975\u63a5\u53d7\u4f53\uff0c\u4f1a\u4e0e\u4eba\u7c7b\u5185\u76ae\u7ec6\u80de\u751f\u957f\u56e0\u5b50A\u53ca\u80ce\u76d8\u6210\u957f\u56e0\u5b50 (placental growth factor\uff0cPlGF) \u7ed3\u5408\u4e14\u4eb2\u5408\u529b\u9ad8\u4e8e\u5176\u81ea\u7136\u63a5\u53d7\u4f53\uff0c\u8fdb\u800c\u6291\u5236\u8fd9\u4e9b\u540c\u6e90\u4eba\u7c7b\u5185\u76ae\u7ec6\u80de\u751f\u957f\u56e0\u5b50\u63a5\u53d7\u4f53\u7684\u7ed3\u5408\u4e0e\u6d3b\u5316\u3002Aflibercept\u4e4b\u9002\u5e94\u75c7\u6709\u6cbb\u7597\u8840\u7ba1\u65b0\u751f\u578b(\u6e7f\u6027)\u5e74\u9f84\u76f8\u5173\u6027\u9ec4\u6591\u90e8\u9000\u5316\u75c5\u53d8\u3001\u4e2d\u592e\u89c6\u7f51\u819c\u9759\u8109\u963b\u585e (CRVO) \u7eed\u53d1\u9ec4\u6591\u90e8\u6c34\u80bf\u6240\u5bfc\u81f4\u7684\u89c6\u529b\u635f\u5bb3\u3001\u7cd6\u5c3f\u75c5\u9ec4\u6591\u90e8\u6c34\u80bf (DME) \u6240\u5bfc\u81f4\u7684\u89c6\u529b\u635f\u5bb3\u7b49\u3002<\/p>\n

\u672c\u836f\u7269\u503c\u5f97\u5173\u6ce8\u7684\u7406\u7531\u5728\u4e8e\u9ad8\u5242\u91cf\u7684Aflibercept\u76f8\u8f83\u4e8e\u4e00\u822c\u5242\u91cf\u7684Aflibercept\uff0c\u5176\u53ef\u51cf\u5c11\u60a3\u8005\u7684\u7ed9\u836f\u9891\u7387\u4e14\u5ef6\u957f\u7ed9\u836f\u4e4b\u5468\u6570\uff0c\u5e76\u540c\u65f6\u5177\u6709\u4e00\u822c\u5242\u91cf\u7684Aflibercept\u8fd1\u4f3c\u4e4b\u6cbb\u7597\u6548\u679c\u548c\u5b89\u5168\u6027\u3002\u5bf9\u4e8e\u75be\u75c5\u4e4b\u60a3\u8005\u4e0e\u4e34\u5e8a\u533b\u5e08\u800c\u8a00\uff0c\u8be5\u7ed9\u836f\u65b9\u5f0f\u6709\u52a9\u4e8e\u6ee1\u8db3\u8be5\u4e9b\u60a3\u8005\u5c1a\u672a\u88ab\u6ee1\u8db3\u7684\u9700\u6c42\u3002\u7b80\u8a00\u4e4b\uff0c\u9ad8\u5242\u91cf\u7684Aflibercept\u51cf\u5c11\u4e86\u6cbb\u7597\u6240\u9700\u7684\u8d1f\u62c5\u3002<\/p>\n

\u9ad8\u5242\u91cf\u7684Aflibercept\u4e8e2029\u5e74\u5728\u6cbb\u7597\u8840\u7ba1\u65b0\u751f\u578b(\u6e7f\u6027)\u5e74\u9f84\u76f8\u5173\u6027\u9ec4\u6591\u90e8\u9000\u5316\u75c5\u53d8\u4e4b\u5e02\u573a\uff0c\u5176\u9884\u671f\u9500\u552e\u989d\u4e3a17.7\u4ebf\u7f8e\u5143\u3002<\/p>\n

\u25cf\u00a0Budesonide<\/strong>[3]<\/a><\/span><\/p>\n

Budesonide\u4e3a\u4e00\u79cd\u91a3\u76ae\u8d28\u7c7b\u56fa\u9187\uff0c\u5177\u6709\u9ad8\u5ea6\u4e4b\u5c40\u90e8\u6297\u53d1\u708e\u6548\u679c\u3002\u65e0\u8bba\u5728\u52a8\u7269\u6216\u4eba\u7c7b\u4e4b\u5b9e\u9a8c\uff0c\u5728\u6fc0\u53d1\u6027\u4e4b\u7814\u7a76\u4e2d\uff0c\u5747\u663e\u793a\u51faBudesonide\u5177\u6709\u6297\u8fc7\u654f\u53ca\u6297\u53d1\u708e\u4e4b\u6548\u679c\u3002Budesonide\u4e4b\u9002\u5e94\u75c7\u6709\u591a\u79cd\uff0c\u4f8b\u5982\u6e83\u75a1\u6027\u7ed3\u80a0\u708e\u3001\u6c14\u5598\u3001A\u578b\u4eba\u7c7b\u514d\u75ab\u7403\u86cb\u767d(IgA)\u80be\u75c5\u53d8 (\u4ea6\u79f0\u8d1d\u683c\u5c14\u6c0f\u75c7\uff0cBerger\u2019s disease) \u7b49\u3002<\/p>\n

\u672c\u836f\u7269\u503c\u5f97\u5173\u6ce8\u7684\u7406\u7531\u5728\u4e8e\u85c9\u7531\u836f\u7269\u63a7\u5236\u91ca\u653e\u6280\u672f\uff0c\u5229\u7528\u80a0\u6eb6\u8863\u7f13\u6162\u91ca\u653e\u5236\u5242\u4e4bBudesonide\uff0c\u53ef\u4fdd\u6301\u8be5\u836f\u7269\u4e4b\u5b8c\u6574\u6027\u4ee5\u5230\u8fbe\u56de\u80a0\uff0c\u5e76\u7528\u4e8e\u6cbb\u7597A\u578b\u514d\u75ab\u7403\u86cb\u767d\u80be\u75c5\u53d8\u3002\u8be5\u836f\u7269\u4e4b\u6cbb\u7597\u76ee\u6807\u4e3a\u9ecf\u819cB\u7ec6\u80de(mucosal B cells)\uff0c\u5305\u62ec\u8d1f\u8d23\u4ea7\u751fIgA\u590d\u5408\u7269\u7684\u57f9\u8036\u6c0f\u6591 (Peyer\u2019s patches)\u3002\u7531\u4e8e\u8be5\u836f\u7269\u4e4b\u5438\u6536\u7279\u6027\uff0c\u4f7f\u8be5\u836f\u7269\u76f8\u8f83\u4e8e\u4e00\u822c\u7684\u91a3\u76ae\u8d28\u7c7b\u56fa\u9187\u800c\u8a00\uff0c\u964d\u4f4e\u4e86\u8bb8\u591a\u91a3\u76ae\u8d28\u7c7b\u56fa\u9187\u6240\u5177\u6709\u7684\u5178\u578b\u526f\u4f5c\u7528\u3002\u7b80\u8a00\u4e4b\uff0c\u7f13\u6162\u91ca\u653e\u5236\u5242\u4e4bBudesonide\u964d\u4f4e\u4e86\u4e00\u822c\u7684\u91a3\u76ae\u8d28\u7c7b\u56fa\u9187\u6240\u5177\u6709\u7684\u5178\u578b\u526f\u4f5c\u7528\u3002<\/p>\n

\u7f13\u6162\u91ca\u653e\u5236\u5242\u4e4bBudesonide\u4e8e2029\u5e74\uff0c\u5176\u9884\u671f\u9500\u552e\u989d\u4e3a7.3\u4ebf\u7f8e\u5143\u3002\u9700\u8865\u5145\u8005\u4e3a\uff0c\u8be5\u836f\u7269\u4e4b\u7279\u6b8a\u6027\u5728\u4e8e\u91a3\u76ae\u8d28\u7c7b\u56fa\u9187\u836f\u7269\u975e\u5e38\u5e38\u89c1\uff0c\u4f46Budesonide\u4e0d\u4ec5\u5728\u4e34\u5e8a\u8bd5\u9a8c\u7684\u7ed3\u679c\u8f83\u4e3a\u7279\u6b8a\u5916\uff0c\u66f4\u6709\u8f83\u4e00\u822c\u7684\u91a3\u76ae\u8d28\u7c7b\u56fa\u9187\u4f4e\u7684\u526f\u4f5c\u7528\u3002<\/p>\n

\u25cf\u00a0Datopotamab deruxtecan<\/strong><\/span><\/p>\n

Datopotamab deruxtecan\u4e3a\u4e00\u79cd\u4f5c\u7528\u4e8e\u6ecb\u517b\u5c42\u7ec6\u80de\u8868\u9762\u6297\u539f2 (trophoblast cell surface antigen 2\uff0cTrop – 2)\u76ee\u6807\u4e4b\u6297\u4f53\u836f\u7269\u590d\u5408\u4f53 (antibody-drug conjugates\uff0cADCs)\u3002\u5176\u9002\u5e94\u75c7\u4e3aHR\u9633\u6027 (HR – positive\uff0cHR\u6307\u8d3a\u5c14\u8499\u63a5\u53d7\u4f53) \/ HER2\u9634\u6027(HER2 – negative\uff0cHER2\u6307\u7b2c\u4e8c\u578b\u4eba\u7c7b\u4e0a\u76ae\u751f\u957f\u56e0\u5b50\u53d7\u4f53)\u548c\u4e09\u9634\u6027 (triple \u2013 negative\uff0c\u4e09\u9634\u6027\u6307ER\u9634\u6027\u548cPR\u9634\u6027\uff0cHER-2\u9634\u6027) \u4e73\u764c\u4e4b\u6cbb\u7597\uff0c\u5176\u4ea6\u5177\u6709\u6cbb\u7597\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08non – small cell lung cancer\uff0cNSCLC\uff09\u4e4b\u529f\u6548\u3002\u6ecb\u517b\u5c42\u7ec6\u80de\u8868\u9762\u6297\u539f2\u76ee\u6807\u9ad8\u5ea6\u8868\u73b0 (> 80 %) \u4e8e\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u7b49\u764c\u75c7\u4e4b\u4e0a\u76ae\u7ec6\u80de (epithelial cancer cells)\uff0c\u800c\u4eba\u7c7b\u5065\u5eb7\u7684\u7ec4\u7ec7\u4e2d\u5219\u8f83\u5c11\u8868\u73b0\uff0c\u6b64\u5dee\u5f02\u4e3a\u4e00\u5177\u5438\u5f15\u529b\u4e4b\u4f5c\u7528\u76ee\u6807\u3002<\/p>\n

Datopotamab deruxtecan\u4e8e\u4e73\u764c\u548c\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u5e02\u573a\u4e2d\uff0c\u524d\u8005\u8be5\u836f\u7269\u5c06\u53ef\u5927\u91cf\u7528\u4e8eHR\u9633\u6027 \/ HER2\u9634\u6027\u4e73\u764c\u60a3\u8005\u4e4b\u540e\u7ebf\u6cbb\u7597\u4e2d\uff0c\u53ca\u65e9\u671f\u4e4b\u4e09\u9634\u6027\u4e73\u764c\u60a3\u8005\u7684\u6cbb\u7597\u4e2d\uff1b\u540e\u8005\u8be5\u836f\u7269\u5219\u53ef\u4f5c\u4e3a\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u60a3\u8005\u4e4b\u65b0\u578b\u7684\u6cbb\u7597\u65b9\u5f0f (\u5373\u4ee5\u524d\u8ff0\u4e4b\u6ecb\u517b\u5c42\u7ec6\u80de\u8868\u9762\u6297\u539f2\u4f5c\u4e3a\u6cbb\u7597\u76ee\u6807)\u3002<\/p>\n

\u672c\u836f\u7269\u503c\u5f97\u5173\u6ce8\u7684\u7406\u7531\u5728\u4e8eDatopotamab deruxtecan\u4e8eHR\u9633\u6027 \/ HER2\u9634\u6027\u4e73\u764c\u7684\u6cbb\u7597\u4e2d\u6709\u66f4\u9ad8\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002\u4e09\u9634\u6027\u4e73\u764c\u4e0e\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u7684\u6cbb\u7597\u9700\u6c42\u532e\u4e4f\u5219\u53ef\u7531\u8be5\u836f\u7269\u6765\u586b\u8865\u3002\u4f46Datopotamab deruxtecan\u4ecd\u9700\u8981\u514b\u670d\u4e00\u4e9b\u969c\u788d\u4f7f\u5176\u80fd\u8131\u9896\u800c\u51fa\uff0c\u56e0\u4e3a\u65e0\u8bba\u662fHR\u9633\u6027 \/ HER2\u9634\u6027\u4e73\u764c\u3001\u4e09\u9634\u6027\u4e73\u764c\u6216\u662f\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u6cbb\u7597\u9886\u57df\uff0c\u65e9\u6709\u4e0a\u5e02\u5df2\u4e45\u4e4b\u56fa\u5b9a\u6cbb\u7597\u836f\u7269\u4e0e\u6cbb\u7597\u65b9\u6cd5\uff0c\u4f8b\u5982\u5185\u5206\u6ccc\u7597\u6cd5(endocrine therapies)\u3001\u82b3\u9999\u9176\u6291\u5236\u5242 (aromatase inhibitor)\u3001\u53e3\u670d\u9009\u62e9\u6027\u96cc\u6fc0\u7d20\u53d7\u4f53\u964d\u89e3\u5242(SERD)\u7b49\uff0c\u53ca\u5728\u65b0\u5174\u6cbb\u7597\u65b9\u6cd5\u4e2d\uff0c\u4f8b\u5982\u5176\u4ed6\u6ecb\u517b\u5c42\u7ec6\u80de\u8868\u9762\u6297\u539f2\u6291\u5236\u5242\u3001\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242(immune checkpoint inhibitors)\u3001\u6838\u7cd6\u805a\u5408\u9176\uff08Poly ADP – ribose polymerase\uff0cPARP\uff09\u6291\u5236\u5242\u3001\u75ab\u82d7\u7b49\u5c06\u4e0eDatopotamab deruxtecan\u76f8\u4e92\u7ade\u4e89\u3002<\/p>\n

\u5728\u4e73\u764c\u548c\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u5408\u5e76\u8ba1\u7b97\u4e0b\uff0cDatopotamab deruxtecan\u4e8e2029\u5e74\uff0c\u5176\u9884\u671f\u9500\u552e\u989d\u4e3a27\u4ebf\u7f8e\u5143\u3002<\/p>\n

\u25cf\u00a0Efanesoctocog alfa<\/strong><\/span><\/p>\n

Efanesoctocog alfa\u4e3a\u4e00\u79cd\u5229\u7528\u521b\u65b0\u6297\u4f53\u7ed3\u6676\u533a\u57df\u7247\u6bb5\u878d\u5408\u6280\u672f(Fc fusion technology)\uff0c\u4e8e\u836f\u7269\u6784\u9020\u4e2d\u52a0\u5165\u7c7b\u8840\u53cb\u75c5\u56e0\u5b50(von Willebrand factor\uff0cVWF)\u4e4b\u7247\u6bb5\u53caXTEN\u00ae\u591a\u80bd(polypeptides)\u8005\u3002Efanesoctocog alfa\u4e4b\u9002\u5e94\u75c7\u4e3a\u6cbb\u7597\u7b2c8\u51dd\u8840\u56e0\u5b50(coagulation factor VIII)\u7f3a\u4e4f\u4e4bA\u578b\u8840\u53cb\u75c5\u3002Efanesoctocog alfa\u7684\u4f7f\u7528\u65b9\u5f0f\u4e3a\u6bcf\u5468\u9759\u8109\u6ce8\u5c04\u7ed9\u836f\u4e00\u6b21\uff0c\u6b64\u79cd\u7ed9\u836f\u65b9\u5f0f\u6709\u52a9\u4e8e\u51cf\u5c11\u73b0\u884c\u4e4b\u7b2c8\u51dd\u8840\u56e0\u5b50\u66ff\u4ee3\u7597\u6cd5\u9700\u8981\u9ad8\u9891\u7387\u6ce8\u5c04\u7ed9\u836f(\u6bcf\u9694\u4e00\u65e5\u7ed9\u4e88\u836f\u7269\u6216\u4e00\u5468\u7ed9\u836f\u4e8c\u6b21)\u7684\u8d1f\u62c5\u3002<\/p>\n

\u672c\u836f\u7269\u503c\u5f97\u5173\u6ce8\u7684\u7406\u7531\u5728\u4e8eEfanesoctocog alfa\u662f\u76ee\u524d\u7a81\u7834\u73b0\u884c\u7c7b\u8840\u53cb\u75c5\u56e0\u5b50\u6cbb\u7597\u9650\u5236\u8005\uff0c\u8be5\u836f\u7269\u589e\u52a0\u4e86\u534a\u8870\u671f\u7684\u9650\u5236(half-life limitation)\uff0c\u4f7f\u63a5\u53d7\u6cbb\u7597\u7684\u8840\u53cb\u75c5\u60a3\u8005\u4e4b\u6ce8\u5c04\u7ed9\u836f\u9891\u7387\u8d1f\u62c5\u964d\u4f4e\u3002\u5373Efanesoctocog alfa\u80fd\u51cf\u5c11\u60a3\u8005\u6cbb\u7597\u4e0a\u7684\u8d1f\u62c5\u3002<\/p>\n

Efanesoctocog alfa\u4e8e2029\u5e74\u4e4b\u5e02\u573a\u9884\u671f\u9500\u552e\u989d\u4e3a17.7\u4ebf\u7f8e\u5143\u3002<\/p>\n

\u25cf\u00a0Ensifentrine<\/strong><\/span><\/p>\n

Ensifentrine\u4e3a\u4e00\u79cd\u78f7\u9178\u4e8c\u916f\u91763 (phosphodiesterase 3\uff0cPDE 3) \u53ca\u78f7\u9178\u4e8c\u916f\u91764 (PDE4) \u7684\u53cc\u91cd\u6291\u5236\u5242\uff0c\u8be5\u836f\u7269\u7cfb\u4ee5\u5438\u5165\u7684\u65b9\u5f0f\u7ed9\u4e88\u836f\u7269\uff0c\u5176\u9002\u5e94\u75c7\u4e3a\u6cbb\u7597\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5(chronic obstructive pulmonary disease\uff0cCOPD)\uff0c\u7528\u4e8e\u4e2d\u5ea6\u81f3\u91cd\u5ea6\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u7684\u60a3\u8005\uff0c\u907f\u514d\u5176\u75c5\u60c5\u52a0\u91cd\u3002Ensifentrine\u7684\u4f18\u52bf\u5728\u4e8e\u5176\u4e0d\u4f1a\u4ea7\u751f\u5e02\u9762\u73b0\u6709\u7684\u53e3\u670d\u78f7\u9178\u4e8c\u916f\u9176\u6291\u5236\u5242\u7684\u5168\u8eab\u6027\u526f\u4f5c\u7528\u3002<\/p>\n

\u672c\u836f\u7269\u503c\u5f97\u5173\u6ce8\u7684\u7406\u7531\u5728\u4e8eEnsifentrine\u4e3a\u73b0\u884c\u6709\u6548\u4e4b\u78f7\u9178\u4e8c\u916f\u91763\u53ca\u78f7\u9178\u4e8c\u916f\u91764\u7684\u53cc\u91cd\u6291\u5236\u5242\uff0c\u5176\u62e5\u6709\u652f\u6c14\u7ba1\u6269\u5f20\u7684\u529f\u6548(bronchodilator)\u548c\u975e\u7c7b\u56fa\u9187\u4e4b\u6297\u53d1\u708e\u6d3b\u6027(nonsteroidal anti – inflammatory activities)\u3002<\/p>\n

Ensifentrine\u4e8e2029\u5e74\u4e4b\u5e02\u573a\u9884\u671f\u9500\u552e\u989d\u4e3a500\u81f37.5\u4ebf\u7f8e\u5143\u3002<\/p>\n

\u53c2\u8003\u6570\u636e\uff1aDrugs to Watch 2024 – New frontiers in medicine,<\/p>\n

<\/a>\u5907\u6ce8\uff1a<\/p>\n

\n
    \n
  1. Clarivate . Clarivate Drugs to Watch Report 2024.\u00a0https:\/\/clarivate.com\/drugs-to-watch\/<\/a>\u00a0(last visited on 20\/01\/2024).<\/li>\n
  2. \u5149\u7530\u7efc\u5408\u533b\u9662\uff0cEYLEA\uff0c\u7f51\u5740\uff1ahttps:\/\/www.ktgh.com.tw\/Medicament_tbDrug_Look.asp?CatID=65&ModuleType=Y&NewsID=1992&Ordid=30988<\/a>\u00a0(\u6700\u540e\u6d4f\u89c8\u65e5\uff1a2024\/01\/20)\u3002<\/li>\n
  3. \u5149\u7530\u7efc\u5408\u533b\u9662\uff0cSYMBICORT\uff0c\u7f51\u5740\uff1ahttps:\/\/www.ktgh.com.tw\/Medicament_tbDrug_Look.asp?CatID=12&ModuleType=Y&NewsID=248&Ordid=28735<\/a>\u00a0(\u6700\u540e\u6d4f\u89c8\u65e5\uff1a2024\/01\/20)\u3002<\/li>\n<\/ol>\n<\/div>\n\n\n\n
    \n\n\n\n
    \n

    \u597d\u6d88\u606f\uff5e\u5317\u7f8e\u667a\u6743\u62a5\u6709\u5fae\u4fe1\u516c\u4f17\u53f7\u4e86\uff01<\/strong><\/span><\/p>\n

    \u300a\u5317\u7f8e\u667a\u6743\u62a5\u300b\u5185\u5bb9\u6db5\u76d6\u4e16\u754c\u5404\u56fd\u7684\u77e5\u8bc6\u4ea7\u6743\u65b0\u95fb\u3001\u91cd\u8981\u7684\u4fb5\u6743\u8bc9\u8bbc\u6848\u4f8b\u5206\u6790\u3001\u6cd5\u89c4\u89e3\u6790\uff0c\u4ee5\u53ca\u4ea7\u4e1a\u4e0e\u6280\u672f\u65b0\u77e5\u7b49\u7b49\u3002<\/p>\n

    \u7acb\u5373\u5173\u6ce8\u5317\u7f8e\u667a\u6743\u5fae\u4fe1\u516c\u4f17\u53f7\u2192 NAIP_IPServices<\/strong><\/p>\n

    \uff5e\u6b22\u8fce\u8bfb\u8005\u5206\u4eab\u4e0e\u8f6c\u53d1\uff5e<\/p>\n<\/td>\n

    		\"\"<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

     <\/p>\n

    \u3010\u672c\u6587\u53ea\u53cd\u6620\u4e13\u5bb6\u4f5c\u8005\u610f\u89c1\uff0c\u4e0d\u4ee3\u8868\u672c\u62a5\u7acb\u573a\u3002\u3011<\/strong><\/p>\n\n\n\n
    \n\n\n\n
    \"\"<\/td>\n<\/td>\n\n\n\n\n\n\n\n\n
    \u4f5c\u8005\uff1a<\/strong><\/td>\n\u90ed\u5ef7\u6fe0<\/strong><\/td>\n<\/tr>\n
    \u73b0\u4efb\uff1a<\/strong><\/td>\n\u8d85\u8d8a\u6cd5\u5f8b\u4e8b\u52a1\u6240\u4e3b\u6301\u5f8b\u5e08<\/td>\n<\/tr>\n
    \u5b66\u5386\uff1a<\/strong><\/td>\n\u53f0\u5927\u836f\u7406\u6240\u7855\u58eb
    \n\u53f0\u79d1\u5927\u4e13\u5229\u6240\u7855\u58eb<\/td>\n<\/tr>\n
    \u4e13\u957f\uff1a<\/strong><\/td>\n1. \u6c11\u4e8b\u3001\u5211\u4e8b\u3001\u884c\u653f\u3001\u533b\u7597\u8bc9\u8bbc
    \n2. \u836f\u4e8b\u3001\u4e13\u5229\u6cd5\u89c4
    \n3. \u751f\u6280\u3001\u533b\u836f\u4e13\u5229
    \n4. \u836f\u7269\u836f\u7406\u5b66<\/td>\n<\/tr>\n
    \u8bc1\u7167\uff1a<\/strong><\/td>\n109\u5e74\u5ea6\u4e2d\u534e\u6c11\u56fd\u4e13\u5229\u5e08\u8003\u8bd5\u53ca\u683c
    \n112\u5e74\u5ea6\u4e2d\u534e\u6c11\u56fd\u5f8b\u5e08\u8003\u8bd5\u53ca\u683c<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

    \u5177\u5f71\u54cd\u529b\u7684\u8c03\u7814\u673a\u6784\u79d1\u777f\u552f\u5b89(CLARIVATE PLC)\u4e8e2024\u5e741\u67088\u65e5\u53d1\u8868\u4e86\u300a2024\u6700\u503c\u5f97\u5173\u6ce8\u7684\u836f\u7269\u300b(Drugs to Watch 2024 – New frontiers in medicine)\u8c03\u7814\u62a5\u544a\uff0c\u62a5\u544a\u5c06\u91cd\u70b9\u653e\u5728\u65b0\u836f\u7684\u53d1\u73b0\u3001\u7814\u53d1\u548c\u65bd\u7528\u6240\u5e26\u6765\u7684\u4e00\u4e9b\u5f71\u54cd\u3002<\/p>\n","protected":false},"author":10,"featured_media":1761,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[254,277,262,255],"tags":[],"author_name1":[330],"class_list":{"0":"post-69370","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-254","8":"category-277","9":"category-262","10":"category-255","11":"author_name1--zh-hans"},"_links":{"self":[{"href":"https:\/\/naipnews.naipo.com\/zh-hans\/wp-json\/wp\/v2\/posts\/69370","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/naipnews.naipo.com\/zh-hans\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/naipnews.naipo.com\/zh-hans\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/naipnews.naipo.com\/zh-hans\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/naipnews.naipo.com\/zh-hans\/wp-json\/wp\/v2\/comments?post=69370"}],"version-history":[{"count":2,"href":"https:\/\/naipnews.naipo.com\/zh-hans\/wp-json\/wp\/v2\/posts\/69370\/revisions"}],"predecessor-version":[{"id":69372,"href":"https:\/\/naipnews.naipo.com\/zh-hans\/wp-json\/wp\/v2\/posts\/69370\/revisions\/69372"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/naipnews.naipo.com\/zh-hans\/wp-json\/wp\/v2\/media\/1761"}],"wp:attachment":[{"href":"https:\/\/naipnews.naipo.com\/zh-hans\/wp-json\/wp\/v2\/media?parent=69370"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/naipnews.naipo.com\/zh-hans\/wp-json\/wp\/v2\/categories?post=69370"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/naipnews.naipo.com\/zh-hans\/wp-json\/wp\/v2\/tags?post=69370"},{"taxonomy":"author_name1","embeddable":true,"href":"https:\/\/naipnews.naipo.com\/zh-hans\/wp-json\/wp\/v2\/author_name1?post=69370"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}